Testimonial

View the full reference (PL)

“As part of its continuous improvement efforts, Polfarmex S.A. decided in 2019 to implement a solution to automate selected administrative processes and streamline document workflows across the organization. Intense Group was selected as the implementation partner and successfully delivered the solution based on Polfarmex’s specific requirements, demonstrating a high level of professionalism, commitment, and project management expertise.”

“Today, the Intense Platform is the primary document management tool at Polfarmex, supporting processes such as incoming and outgoing correspondence, contract management, Helpdesk requests, and leave applications. In certain areas, the platform is also used to register and manage projects and work schedules, with access to Gantt charts that visualize project plans and the progress of individual tasks.”

“In summary, the Intense Platform has become an essential tool used by the majority of our employees. It has streamlined our business processes, improved information flow — including data exchange with external systems such as SAP — and optimized project management. It is certainly one of those IT solutions we would confidently recommend.”

Michał Sambor

Technical Director

Company description

Polfarmex is a Polish pharmaceutical company with a manufacturing facility in Kutno, specializing in the production of prescription and over-the-counter (OTC) generic medicines.

Polfarmex S.A., headquartered in Kutno, is a Polish family-owned pharmaceutical company with 100% Polish capital, operating since 1989. Originally established as Polfa-Farmex, the company changed its name to Polfarmex in 1994 and was transformed into a joint-stock company in January 2000.

The company specializes in the production of generic medicines, over-the-counter (OTC) pharmaceuticals, and dietary supplements. In 2003, Polfarmex introduced the first generic equivalent of a modified-release indapamide medicine, and in 2015, it began manufacturing the world’s first generic equivalent of a combination medicine containing fluticasone and salmeterol.

In 2017, Polfarmex established a biotechnology laboratory focused on developing production technologies for biosimilar medicines, with particular emphasis on human insulin analogues.

The company currently employs more than 700 people, and some of its products are available in several international markets. Marek Wośko, a second-generation member of the founding family, continues to serve as President of the Management Board.

Today, Polfarmex’s portfolio includes more than 100 products, some of which are also available in international markets.

Polfarmex S.A. at a glance:

  • 30+ years of experience in the pharmaceutical industry
  • 100% Polish-owned capital
  • 100+ products in its portfolio
  • 790 employees
  • Presence in 15 international markets

Contact

Choose a contact method

Need more information?
Contact us.

    Contact us